Insider · CIK 0001802188

Davis Blaine

Reports to the SEC for 2 companies · FREDERICK, MD

sec.gov

Transactions

Companies

Filings

CIK

0001802188

Forms 4 and 5

Insider transactions

17 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-06	RNACCartesian Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−10.6K sh	$6.82	−$72.2K	121,220
2026-01-02	RNACCartesian Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+37K sh	—	—	131,811
2026-01-02	RNACCartesian Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+109K sh	—	—	109,000
2025-01-06	RNACCartesian Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,028 sh	$16.83	−$67.8K	94,811
2025-01-03	RNACCartesian Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,961 sh	$16.72	−$66.2K	98,839
2025-01-02	RNACCartesian Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+64.6K sh	—	—	64,600
2025-01-02	RNACCartesian Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+22K sh	—	—	102,800
2024-01-02	RNACCartesian Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+2.42M sh	—	—	2,424,000
2024-01-02	RNACCartesian Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+3.11M sh	—	—	3,110,000
2023-11-13	RNACCartesian Therapeutics, Inc. · Employee Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−1.25M sh	$0.79	−$988K	0
2022-11-28	RNACCartesian Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+1.25M sh	—	—	1,250,000
2022-07-15	TARAProtara Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−5,081 sh	$3.13	−$15.9K	20,662
2022-01-03	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+84.8K sh	—	—	84,800
2022-01-03	TARAProtara Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+14.1K sh	—	—	15,581
2021-01-19	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2020-09-22	TARAProtara Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+1,481 sh	$16.91	+$25K	1,481
2020-02-11	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+94K sh	—	—	94,000

Recent filings

Accepted (ET)
Jan 84
Davis Blaine0001453687-26-000045
SEC(opens sec.gov)
Jan 64
Davis Blaine0001453687-26-000033
SEC(opens sec.gov)
Jan 74
Davis Blaine0001453687-25-000035
SEC(opens sec.gov)
Jan 64
Davis Blaine0001453687-25-000025
SEC(opens sec.gov)
Jan 44
Davis Blaine0001453687-24-000027
SEC(opens sec.gov)
Nov 154
Davis Blaine0001453687-23-000089
SEC(opens sec.gov)
Nov 304
Davis Blaine0001453687-22-000143
SEC(opens sec.gov)
Jul 194
Davis Blaine0001213900-22-040317
SEC(opens sec.gov)
Jan 54
Davis Blaine0001209191-22-001715
SEC(opens sec.gov)
Jan 214
Davis Blaine0001209191-21-004653
SEC(opens sec.gov)
Sep 234
Davis Blaine0001209191-20-051631
SEC(opens sec.gov)
Feb 114
Davis Blaine0001209191-20-008531
SEC(opens sec.gov)

Companies

Address

C/O CARTESIAN THERAPEUTICS, INC. 7495 NEW HORIZON WAY

FREDERICK, MD, 21703